The European market has recently seen a boost, with the pan-European STOXX Europe 600 Index rising as geopolitical tensions eased and economic stimulus measures were announced. Amidst this backdrop, investors might find opportunities in penny stocks—an investment area that remains relevant despite its somewhat outdated terminology. These smaller or newer companies can offer significant growth potential when backed by strong financials, and we will explore three such examples that may present hidden value for investors seeking quality at an affordable price point.
Top 10 Penny Stocks In Europe
| Name | Share Price | Market Cap | Rewards & Risks |
| Orthex Oyj (HLSE:ORTHEX) | €4.53 | €80.45M | ✅ 4 ⚠️ 1 View Analysis > |
| Maps (BIT:MAPS) | €3.53 | €46.89M | ✅ 4 ⚠️ 2 View Analysis > |
| Angler Gaming (NGM:ANGL) | SEK3.60 | SEK269.95M | ✅ 4 ⚠️ 2 View Analysis > |
| Cellularline (BIT:CELL) | €2.79 | €58.85M | ✅ 4 ⚠️ 2 View Analysis > |
| Fondia Oyj (HLSE:FONDIA) | €4.45 | €16.64M | ✅ 2 ⚠️ 3 View Analysis > |
| Abak (WSE:ABK) | PLN4.22 | PLN11.37M | ✅ 2 ⚠️ 4 View Analysis > |
| Bredband2 i Skandinavien (OM:BRE2) | SEK2.455 | SEK2.35B | ✅ 4 ⚠️ 1 View Analysis > |
| Hifab Group (OM:HIFA B) | SEK3.60 | SEK219.02M | ✅ 2 ⚠️ 2 View Analysis > |
| Deceuninck (ENXTBR:DECB) | €2.065 | €285.1M | ✅ 3 ⚠️ 1 View Analysis > |
| Netgem (ENXTPA:ALNTG) | €0.984 | €33.18M | ✅ 3 ⚠️ 2 View Analysis > |
Click here to see the full list of 325 stocks from our European Penny Stocks screener.
Let's uncover some gems from our specialized screener.
Fermentalg (ENXTPA:ALGAE)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Fermentalg SA is engaged in the development, production, and sale of active ingredients derived from microalgae for various sectors including food, health, nutrition, and environment on a global scale with a market cap of €47.37 million.
Operations: Fermentalg's revenue is primarily generated from its biotechnology segment, amounting to €11.50 million.
Market Cap: €47.37M
Fermentalg SA, with a market cap of €47.37 million, operates in the biotechnology sector and is currently unprofitable. Despite its financial challenges, the company has shown financial prudence by reducing its debt-to-equity ratio from 62.3% to 38.5% over five years and maintaining more cash than total debt. Its short-term assets of €26.7 million comfortably cover both short-term (€10.7M) and long-term liabilities (€7.7M). The stock's weekly volatility remains high compared to most French stocks, reflecting potential risks for investors interested in penny stocks with volatile share prices but stable cash runway prospects exceeding three years.
- Dive into the specifics of Fermentalg here with our thorough balance sheet health report.
- Learn about Fermentalg's future growth trajectory here.
ATEME (ENXTPA:ATEME)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: ATEME SA, along with its subsidiaries, produces and sells electronic and computer devices and instruments across Europe, the Middle East, Africa, the United States, Canada, Latin America, and the Asia Pacific regions; it has a market cap of €53.54 million.
Operations: The company generates €93.50 million in revenue from the marketing of professional compression and video broadcasting solutions.
Market Cap: €53.54M
ATEME SA, with a market cap of €53.54 million, operates in the competitive video broadcasting solutions market. Despite being unprofitable and experiencing increased losses over five years, it maintains a positive cash flow and sufficient cash runway for over three years. The stock trades at a significant discount to its estimated fair value, presenting potential value opportunities despite high volatility compared to most French stocks. Recent advancements include showcasing cloud-native NextGen TV technology at NAB 2025, highlighting ATEME's innovative approach in transitioning broadcast systems to more efficient cloud-based solutions while reducing infrastructure costs.
- Click here to discover the nuances of ATEME with our detailed analytical financial health report.
- Assess ATEME's future earnings estimates with our detailed growth reports.
Uniphar (ISE:UPR)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Uniphar plc is a diversified healthcare services company operating in the Republic of Ireland, the United Kingdom, the Netherlands, and internationally with a market cap of €973.40 million.
Operations: The company generates revenue through its Pharma segment (€658.81 million), Medtech segment (€267.97 million), and Supply Chain & Retail segment (€1.84 billion).
Market Cap: €973.4M
Uniphar plc, with a market cap of €973.40 million, demonstrates robust revenue streams across its Pharma (€658.81 million), Medtech (€267.97 million), and Supply Chain & Retail segments (€1.84 billion). The company benefits from seasoned management and board experience, contributing to high-quality earnings and a satisfactory net debt to equity ratio of 36.8%. Despite low return on equity (16%), Uniphar's earnings have grown significantly by 43.3% over the past year, outpacing industry averages. However, short-term liabilities exceed assets (€630.7M vs €553.8M), indicating potential liquidity challenges despite stable weekly volatility at 5%.
- Unlock comprehensive insights into our analysis of Uniphar stock in this financial health report.
- Understand Uniphar's earnings outlook by examining our growth report.
Next Steps
- Take a closer look at our European Penny Stocks list of 325 companies by clicking here.
- Contemplating Other Strategies? Outshine the giants: these 23 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Fermentalg might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com